Immorta Bio Reports Successful Inhibition of Lung Cancer Growth by Senolytic Immunotherapy Product SenoVax™

1 year ago 39

/PRNewswire/ -- Immorta Bio Inc, a science-based Life Extension company announced today positive preclinical findings utilizing its senescent cell-killing...

Read Entire Article

Immorta Bio Reports Successful Inhibition of Lung Cancer Growth by Senolytic Immunotherapy Product SenoVax™

Related

GSK receives EU orphan drug designation for B7-H3 ADC in lun...

Genprex Collaborators Report Positive Preclinical Data on th...

Combo First to Show Overall Survival Benefit in Certain Colo...

Trending

Popular

Darwin woman forced to fly interstate for a cancer diagnosis...

Reduce your risk of cancer: get involved and have fun

Stone Roses legend’s wife dead aged 52 after long cancer bat...

B.C. woman raises awareness of pancreatic cancer after husba...

Former OU 2-sport standout Ryan Minor has no more treatment ...